Tetracycline pop up box.doc


Antibiotic Class:
Antimicrobial Spectrum:
Staphylococcus aureus, Streptococcus pneumonia, Streptococcus pyogenes, Streptooccus
agalacticae, Campylobacter jejuni, Haemophilus influenzae, Neisseria gonorrhoeae, Neisseria
meningitides,Clostridium spp., Peptostreptococcus spp., Peptococcus spp. Bacteroides
melaninogenicus, Bacteroides fragilis

Mechanism of Action:
Inhibits bacterial protein synthesis by binding with the 30S ribosomal subunit.

Tetracyclines produce a combination of concentration and time-dependent killing (AUC:MIC

Dose of 500mg PO: Cmax: 1.5-5 mcg/mL; Tmax: 2-4 hours; Half-life: 6-12 hours; Volume of
distribution: 108 L/kg; Table 3
Adverse Effects:
GI: epigastric burning, abdominal discomfort, nausea, vomiting, anorexia, diarrhea, esophagitis,
esophageal ulcers, dysphagia, candidal superinfections
Teeth and bone: (dose/duration related) yellow discoloration of teeth, which turns into a gray-
brown permanent discoloration, hypoplasia of enamel, teeth demineralization, skeletal growth
Hepatotoxicity: rare, but fatal; intrahepatic cholestasis, jaundice, azotemia, acidosis, irreversible
Renal Toxicity: hyperphosphatemia, acidosis, polyuria, polydipsia
Photosensitivity and hyperpigmentation: red rash to blistering on sun-exposed areas;
photoallergic reactions manifested by paresthesias of hands, feet, nose, photo-onycholysis
Auditory: tinnitus, hearing loss
Vision: visual disturbances
CNS: lightheadedness, dizziness, ataxia, drowsiness, headache
Oral: 250mg, 500mg capsules
Adult dosing (common indications):
Acne vulgaris: 250 mg PO q other day to 500 mg PO q24h
Bartonellosis: 1-2 g/day divided PO in 2-4 doses
Brucellosis: 500 mg PO q6h 4 x 3 plus streptomycin
Chlamydia psitacci infection: 1-2 g/day divided PO in 2-4 doses
Rickettsial disease: 1-2 g/day divided PO in 2-4 doses
Nongonococcal urethritis: 500 mg PO q6h x 7 days
Pediatric dosing:
25-50mg/kg/day in 2 to 4 divided doses OR 0.6-1.2g/m2 in 2 – 4divided doses
Table 4

Disease state based dosing:
Renal failure: CrCl > 50mL/min: 250mg to 500mg q6h
CrCl 10-50 mL/min: 250mg to 500mg q12h to q24h Hepatic failure: No dosing changes recommended at this time.
Contraindications: Hypersensitivity to tetracycline antibiotics.
Precautions: Usage in newborns, infants, and children less than 8 years of age; risk for tooth
discoloration; Renal or liver impairment; Phototoxicity; Veneral disease with suspected
coexistent syphilis
Drug Interactions:
Oral contraceptives: Decreased contraceptive effectiveness
Warfarin: Increased warfarin effect
Barbiturates, phenytoin, carbamazepine: Decreased serum concentrations of doxycycline
Ethanol: Decreased doxycyline serum concentrations
Antacids, didanosine, sucralfate, multivitamins: decreased tetracycline absorption
Kaolin, bismuth subsalicylate: decreased absorption of tetracycline
Food: Decreased absorption of tetracycline
Milk: Decreased absorption of tetracycline
Table 6

Category D: Risk established, but benefits may outweigh risk.
Monitoring Requirements:
Therapeutic: Culture and sensitivities, serum levels, signs and symptoms of infection, white
blood cell count
Toxic: Hypersensitivity syndrome reaction, serum sickness like reaction or single organ
dysfunction – Monitor: CBC, LFTs, urinalysis, urea, creatinine, chest radiograph; Drug-induced
lupus: monitor antinuclear antibody and hepatic transaminases; General long-term therapy:
Liver and renal function tests, Hematopoietic studies
Brand names/Manufacturer:
Available by many names and manufacturers

Source: http://www.antimicrobe.org/new/drugpopup/Tetracycline.pdf

Tentative list of candidates for graduation 3rd 09-10 for website1.xls

Tentative List of Candidates for Graduation 3rd Term, 2009-2010 Commencement Exercises, July 3, 2010 STUDENT NAME Aban, Ness Sheen T. Abanto, Catherine S. Abanto, Darlyn Robey Q. Abrahan, Andrea Ionica L. Adela, Ronald Joshua R. Agcaoili, Angelique Nicole A. Agtarap Jr., Hector R. Aguasin, Maria Aurora R. Aguila, Gian Paolo R. Aguilar, Gian Marco A. Alapa


Drug Information Journal; Vol. 34, pp. 129-136,2000Printed in the USA. All rights reserved. Copyright © 2000 Drug Information Association Inc. USE OF PEN-BASED ELECTRONIC DIARIES IN AN INTERNATIONAL CLINICAL TRIAL OF ASTHMA BRIAN TIPLADY AND AUDREY H. JAMIESON AstraZeneca Clinical Research Edinburgh, Edinburgh, United Kingdom GRAHAM K. CROMPTON Western General Hospital, Edinbu

Copyright © 2010-2014 Internet pdf articles